NG Biotech has obtained the Rapid Diagnostic Orientation Test (TROD) label for its NG-Test® IgG-IgM COVID-19 serological test following the ministerial decree of the 10th of July. With this TROD status, private doctors and pharmacists can now use our rapid diagnostic serological test for the possible presence of antibodies (IgG / IgM) against the COVID-19 virus.
Great ease of use
Our rapid diagnostic serological test is the only “all in one” concept. It is therefore without manipulation, very easy to use, practical and hygienic. Blood collection is secure and controlled: the volume collected is always the same and ensures the reliability of the test.
It allows from a simple drop of blood taken at the fingertip and in fifteen minutes, to search for the possible presence of antibodies (IgG / IgM) directed against SARS-CoV-2. The patient therefore knows if he has been in contact with the virus.
Claimed for several weeks by pharmacists and liberal doctors to meet the demands of French people wishing to know their immune status, our test is an important tool in the strategy of prevention and epidemiological investigation, in accordance with the recommendations of the High Health Authority (HAS).
Proven use in hospitals and the military
Validated by the Institut Pasteur and referenced by the HAS, NG-Test® IgG-IgM COVID-19 was previously distributed in hospitals and the military. As early as April, NG Biotech obtained orders from the AP-HP and the Rennes University Hospital which is currently carrying out a serological prevalence study among 13,000 caregivers.
Our test is also used by the Ministry of the Armed Forces and a contract is signed with the General Directorate of Health for distribution to the Regional Health Agencies.
It has been the subject of 8 clinical evaluations and several international publications.
To know more: https://ngtest-covid-19.com/
